Open access

Regulation of tumor growth by leukocyte-specific protein 1 in T cells
Riri Kwon, Bong-Ki Hong, Kang-Gu Lee, Eunbyeol Choi, Laurent Sabbagh, Chul-Soo Cho, Naeun Lee, Wan-Uk Kim

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e001180; DOI: 10.1136/jitc-2020-001180
Impact of anatomic site on antigen-presenting cells in cancer
Maria Zagorulya, Ellen Duong, Stefani Spranger

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e001204; DOI: 10.1136/jitc-2020-001204
Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
Alissa Keegan, Biagio Ricciuti, Padric Garden, Limor Cohen, Reiko Nishihara, Anika Adeni, Cloud Paweletz, Julianna Supplee, Pasi A Jänne, Mariano Severgnini, Mark M Awad, David R Walt

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e000678; DOI: 10.1136/jitc-2020-000678
Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
Karla A Lee, Heather Shaw, Véronique Bataille, Paul Nathan

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e000577; DOI: 10.1136/jitc-2020-000577
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
Natalia Rodrigues Mantuano, Marina Natoli, Alfred Zippelius, Heinz Läubli

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e001222; DOI: 10.1136/jitc-2020-001222
CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
Hongfei Wang, Yixuan Sun, Xiuman Zhou, Chunxia Chen, Ling Jiao, Wanqiong Li, Shanshan Gou, Yanying Li, Jiangfeng Du, Guanyu Chen, Wenjie Zhai, Yahong Wu, Yuanming Qi, Yanfeng Gao

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e000905; DOI: 10.1136/jitc-2020-000905
Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
Jamie S Lin, Daniel Y Wang, Omar Mamlouk, William F Glass, Maen Abdelrahim, Cassian Yee, Ala Abudayyeh

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e001287; DOI: 10.1136/jitc-2020-001287
Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer
Shang-Jui Wang, Karishma Khullar, Sinae Kim, Nikhil Yegya-Raman, Jyoti Malhotra, Roman Groisberg, Samuel H Crayton, Ann W Silk, John L Nosher, Michael A Gentile, Janice M Mehnert, Salma K Jabbour

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e000889; DOI: 10.1136/jitc-2020-000889
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
Anne Y Lai, Jessica A Sorrentino, Konstantin H Dragnev, Jared M Weiss, Taofeek K Owonikoko, Julie A Rytlewski, Jill Hood, Zhao Yang, Rajesh K Malik, Jay C Strum, Patrick J Roberts

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e000847; DOI: 10.1136/jitc-2020-000847
Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab
Yutaka Natori, Eisaku Sasaki, Shu Soeda, Shigenori Furukawa, Yusuke Azami, Emi Tokuda, Takashi Kanbayashi, Shigehira Saji

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e001164; DOI: 10.1136/jitc-2020-001164

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages